All News

psA.fil_.Hands_.jpg

Evaluation of Bimekizumab in PsA

Antoni Chan, MD, PhD

Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.

Read Article
US.knee_.jpg

Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care

Jiha Lee, MD

Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and Psoriatic Arthritis.” This is the first update in a decade since the 2012 ACR guidance on the reasonable use of MSUS in rheumatology clinical practice.

Read Article
EULAR19.abstract.jpg (keep)

ACR 2024 - Featured Industry Presentations

Jack Cush, MD

ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
Can multidisciplinary clinics improve quality of care for PsA? Abstract 0596: Multidisciplinary care in PsA associated with ↓ time to first biologic, ↑ dermatology & nurse visits, and better CV risk assessment. #ACR24 @RheumNow https://t.co/2OnUR6te63

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
The METEOR study reveals distinct clinical features in spondyloarthritis (SpA) patients with vs. without IBD. Key features of those with IBD: - Lower male prevalence - Higher uveitis rates - Lower psoriasis rates - More structural damage in SI joints Mirroring gut… https://t.co/EyBZQ91DDn

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

🚨Therapeutic target in PsO? Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO). - HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4. - Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI

Links:

Adela Castro AdelaCastro222 ( View Tweet)
🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
High PBO effect in PsA studies Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12: 💡PBO rates significantly increased over time. 💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe

Links:

Adela Castro AdelaCastro222 ( View Tweet)

#0582🔬Challenges in Achieving PsA Disease Control ➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively 🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes. 🩺Unmet needs remain in PsA; tailored Rx needed #ACR24 @RheumNow

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

The rising placebo response rates in PsA trials are linked to global recruiting patterns, with more studies in less affluent countries. Limited access to healthcare may drive this trend, highlighting the need for awareness among stakeholders. Plenary Abstr#0722… https://t.co/FplpSlIamR https://t.co/NIp76IS6TZ

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Kerschbaumer et al. Rising placebo rates in PsA RCTs appear linked to changes in global recruitment patterns. Dramatic relationship between GNI and placebo response rate. Crucial information for properly planning future trials @RheumNow #ACR24 Abstr#0772 https://t.co/PtHs2RXe0f https://t.co/OKG6czQrYD

Links:

Richard Conway RichardPAConway ( View Tweet)
Location of research matters Ab#0772 Global recruiting patterns impact PBO in PsA PBO results improve w time - 0.9%/year More globalization of trials w time Gross nation index (GNI) neg ass w ACR20 - inclusion of less affluent controls affects higher PBO response @RheumNow #ACR24

Eric Dein ericdeinmd ( View Tweet)

TNFi cycling vs. switching to IL-17Ai? Dr @AlexisOgdie et al from CorEvitas registry: PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF) Not stat significant but offers alternative Tx options @RheumNow #ACR24 abs585 https://t.co/8m347BRM75

Links:

sheila RHEUMarampa ( View Tweet)
Dr. Catherine Bakewell @CatherineB27 shares the preliminary ACR guidelines on ultrasound imaging in psoriatic arthritis covering 4 domains, detailed PICOs covering the early phase, diagnosis, assessment covering the domains of PsA @RheumNow #ACR24 https://t.co/DoHE1rsSGf

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Dactylitis management in PsA: Acute: pain and swelling Chronic: painless swelling Broad ddx No role for LEF or SSZ #ReviewCourse #ACR24 @RheumNow https://t.co/KZXv1UvhXn

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Great summary of treatment choices in PsA: 1. Identify domain involved 2. Identify comorbidities/pt preferences 3. Still unmet needs for ttx in inflammatory eye disease #ACR24 @rheumnow https://t.co/1WMnkDYvip

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX

Links:

Patricia Harkins DrTrishHarkins ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

Pain in PsA = predictor of disability and QoL TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated biomarkers vs PBO @RheumNow #ACR24 Abstract #2366 https://t.co/DAgmdmmTE0

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×